Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Oncoscience AG

Home Clinical Trial Sponsors and OrganizationsOncoscience AG

Oncoscience AG

ACTIVE

Zurich, Switzerlandwww.oncoscienceag.comPrivate

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

8

4 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 2

1

12.5%

Phase 3

1

12.5%

Trial Status Distribution

Active, not recruiting

4

50.0%

Completed

4

50.0%

Clinical Trials

Trials sponsored by this organization (8)

Nimotuzumab in Adults With Pancreatic Cancer

Sep 2007188 participants

Nimotuzumab in Adults With Glioblastoma Multiforma

Aug 2007150 participants

A RANDOMIZED, MULTICENTER, PHASE IIB/IIIA STUDY OF GEMCITABINE AND THE MONOCLONAL ANTIBODY NIMOTUZUMAB (OSAG 101) VERSUS GEMCITABINE AND PLACEBO FOR THE TREAMENT OF CHEMOTHERAPY-NAIVE PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER

Active, not recruiting

Phase-III study of standard radiotherapy plus concomitant and adjuvant OSAG 101 (Theraloc®) plus Temozolomide vs. standard radiotherapy plus concomitant and adjuvant Temozolomide in patient with newly diagnosed, histologically confirmed glioblastoma multiforme grade IV

Active, not recruiting

Phase III study on the effectiveness of OSAG 101 Theraloc in newly diagnosed intrinsic pontine gliomas of children and adolescents - ND

Active, not recruiting

May 200640 participants

Nimotuzumab in Children With Intrinsic Pontine Glioma

Apr 200641 participants

Phase III Study on the effectiveness of OSAG 101 (Theraloc) in newly diagnosed intrinsic pontine gliomas of children and adolescents - N.A.

Active, not recruiting

Nov 200540 participants

Nimotuzumab in Children With HGG

Jun 200445 participants

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials8
Approvals
News

Back to Organizations